Please login to the form below

Not currently logged in
Email:
Password:

Biocon

This page shows the latest Biocon news and features for those working in and with pharma, biotech and healthcare.

Amgen CEO says Aimovig is “one of most successful launches”

Amgen CEO says Aimovig is “one of most successful launches”

of weakness from biosimilar competition after Mylan/Biocon launched their Fulphila rival in July.

Latest news

  • Roche eyes September FDA verdict for triple NSCLC therapy Roche eyes September FDA verdict for triple NSCLC therapy

    Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.

  • Novartis doubles down on biosimilars with Biocon alliance Novartis doubles down on biosimilars with Biocon alliance

    Novartis doubles down on biosimilars with Biocon alliance. The companies will develop multiple immunology and oncology biosimilars. ... Already a big player in the emerging biosimilars market, Novartis has struck a deal with India’s Biocon in a bid to

  • Mylan gets first biosimilar Herceptin OK from FDA Mylan gets first biosimilar Herceptin OK from FDA

    The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... Mylan said in a statement Ogivri is the

  • First Herceptin biosimilar cleared in Europe First Herceptin biosimilar cleared in Europe

    favour of approval for Biocon and Mylan’s version of the drug in September. ... Biocon and Mylan withdrew the filing for their biosimilar in the EU, after questions were raised about manufacturing quality compliance issues, but said recently these have

  • Amgen's Mvasi is first FDA-approved cancer biosimilar Amgen's Mvasi is first FDA-approved cancer biosimilar

    Mvasi reaches the market ahead of rival Avastin biosimilars from Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan that are all in late-stage development.

More from news
Approximately 9 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Similarly, Bristol-Myers Squibb has called time on its deal with Biocon for IN-105/Tregopil [oral insulin]. ... Given the cost of the clinical studies going forwards, Biocon will now be seeking a new partner.

  • Pharma deals during February 2013 Pharma deals during February 2013

    Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... Mylan and Biocon will share development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics